Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis

Lina Sheng,Xiaofei Li,Fangbin Weng,Shuang Wu,Yongxin Chen,Lianqing Lou

DOI: https://doi.org/10.1155/2022/5071816

2022-11-26

Journal of Tropical Medicine

Abstract:Background. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Relevant randomized controlled trials (RCTs) were retrieved by searching the PubMed, Embase, Cochrane's Library, Web of Science, Wanfang, and CNKI databases. A random-effects model was used to combine the results. Results. 18 RCTs with 2630 patients were included in this meta-analysis. Pooled results showed that adjunctive rhuIL-2 significantly increased the odds of sputum culture conversion to negative (risk ratio [RR]: 1.27, 95% CI: 1.09 to 1.47, p = 0.002 , I2 = 80%), sputum smear conversion to negative (RR: 1.35, 95% CI: 1.17 to 1.57, p 0.05). Conclusions. rhuIL-2 is an effective adjunctive immunotherapy for patients with pulmonary tuberculosis.

public, environmental & occupational health,tropical medicine

What problem does this paper attempt to address?

### What problems does this paper attempt to solve?

This review article aims to evaluate the efficacy and safety of recombinant human interleukin - 2 (rhuIL - 2) as an adjuvant therapeutic drug in adult patients with pulmonary tuberculosis through systematic review and meta - analysis. Specifically, the study attempts to answer the following questions:

1. **Can rhuIL - 2 increase the sputum culture negative conversion rate?** That is, whether the use of rhuIL - 2 can more effectively clear Mycobacterium tuberculosis in patients' sputum.
2. **Can rhuIL - 2 increase the sputum smear negative conversion rate?** That is, whether the use of rhuIL - 2 can more effectively reduce the number of Mycobacterium tuberculosis in sputum.
3. **Can rhuIL - 2 improve the absorption of imaging lesions?** That is, whether the use of rhuIL - 2 can accelerate the healing of lung lesions.
4. **Can rhuIL - 2 promote cavity closure?** That is, whether the use of rhuIL - 2 can make the lung cavities heal faster.
5. **How is the safety of rhuIL - 2?** That is, whether the use of rhuIL - 2 will cause serious adverse reactions, leading to treatment interruption.

In addition, the study also explored whether the efficacy and safety of rhuIL - 2 in different types of pulmonary tuberculosis patients (such as multi - drug - resistant pulmonary tuberculosis patients and newly - treated and retreated patients) are consistent.

### Research background

Pulmonary tuberculosis (TB) is a major infectious disease caused by Mycobacterium tuberculosis (Mtb) infection and is an important issue in global public health. As of 2020, the World Health Organization (WHO) estimated that there were 9.9 million new cases and 1.28 million deaths worldwide. Currently, standard chemotherapy is the basis for the treatment of pulmonary tuberculosis, but there are problems such as long treatment courses, serious side effects, poor compliance, and drug resistance. Therefore, the development of new adjuvant therapies is of great significance for clinical medicine and public health.

Studies have shown that the host's immune capacity plays a key role in the occurrence, development, and outcome of pulmonary tuberculosis. Activated macrophages and specific T cells protect the host from Mycobacterium tuberculosis through production and interaction. Therefore, treatment methods that enhance protective immunity or regulate adaptive immunity may become potential adjuvant therapies for patients with advanced pulmonary tuberculosis. Recombinant human interleukin - 2 (rhuIL - 2), as a cytokine related to T1 - type immune response, plays an important role in immune activation and regulation, and has been proven to enhance the proliferation and transformation of CD4+ T cells and NK cells, thereby potentially enhancing the anti - tuberculosis effect of standard chemotherapy.

However, previous research results on rhuIL - 2 as an adjuvant treatment for pulmonary tuberculosis are inconsistent, and it is still unclear whether its efficacy and safety in drug - resistant and recurrent pulmonary tuberculosis patients are similar. Therefore, this study comprehensively summarizes the efficacy and safety of rhuIL - 2 in adult patients with pulmonary tuberculosis through meta - analysis.

### Conclusion

The research results show that rhuIL - 2, as an adjuvant treatment for the standard chemotherapy of pulmonary tuberculosis, can significantly increase the sputum culture negative conversion rate, sputum smear negative conversion rate, imaging lesion absorption rate, and cavity closure rate, and has not been found to be associated with any serious adverse events. These findings indicate that rhuIL - 2 is an effective adjuvant immunotherapy for pulmonary tuberculosis patients receiving standard chemotherapy.